Cwm, LLC Chemo Centryx, Inc. Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

Shares

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Oct 27, 2022	BUY	$22.17 - $51.8 $886 - $2,072	40 Added 4.0%	1,040 $54,000
Q1 2022 Apr 21, 2022	SELL	$22.22 - $39.12 $488 - $860	-22 Reduced 2.15%	1,000 $25,000
Q4 2021 Jan 31, 2022	SELL	$18.38 - $40.5 $771 - $1,701	-42 Reduced 3.95%	1,022 $37,000
Q4 2020 Sep 15, 2021	SELL	$47.25 - $65.16 $330 - $456	-7 Reduced 0.65%	1,064 $14,000
Q4 2020 Jan 27, 2021	BUY	$47.25 - $65.16 $330 - $456	7 Added 0.66%	1,071 $66,000
Q3 2020 Sep 15, 2021	BUY	$46.35 - $61.69 $2,966 - $3,948	64 Added 6.4%	1,064 $14,000
Q3 2020 Oct 19, 2020	SELL	$46.35 - $61.69 $2,966 - $3,948	-64 Reduced 6.02%	1,000 $55,000
Q2 2020 Sep 15, 2021	BUY	$38.58 - $65.07 $2,469 - $4,164	64 Added 6.4%	1,064 $14,000
Q2 2020 Jul 22, 2020	SELL	$38.58 - $65.07 $2,469 - $4,164	-64 Reduced 6.02%	1,000 $58,000
Q1 2020 Sep 15, 2021	BUY	$32.73 - $50.78 $2,094 - $3,249	64 Added 6.4%	1,064 $14,000
Q1 2020 Apr 28, 2020	SELL	$32.73 - $50.78 $2,094 - $3,249	-64 Reduced 6.02%	1,000 $40,000
Q4 2019 Sep 14, 2021	BUY	$6.81 - $39.55 $435 - $2,531	64 Added 6.4%	1,064 $14,000
Q4 2019 Jan 27, 2020	SELL	$6.81 - $39.55 $435 - $2,531	-64 Reduced 6.02%	1,000 $40,000
Q3 2019 Sep 14, 2021	BUY	$6.47 - $8.96 $6,884 - $9,533	1,064 New	1,064 $14,000
Q3 2019 Oct 22, 2019	SELL	$6.47 - $8.96 $6,884 - $9,533	-1,064 Closed	0 $0
Q2 2019 Sep 14, 2021	BUY	$8.31 - $14.85 $8,841 - $15,800	1,064 New	1,064 $14,000
Q2 2019 Jul 31, 2019	SELL	$8.31 - $14.85 $8,841 - $15,800	-1,064 Closed	0 $0
Q1 2019 Sep 02, 2021	BUY	$10.01 - $13.89 $10,650 - $14,778	1,064 New	1,064 $0

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.